Table 4.
Association between baseline clinical variables, laboratory data, and postrandomization stroke events in univariable (left) and multivariable models (right)
| Variable | Hazard Ratio (95% Confidence Interval) | P Value | Hazard Ratio (95% Confidence Interval) | P Value |
|---|---|---|---|---|
| Sex, women/men | 2.14 (1.33 to 3.45) | 0.002 | 2.15 (1.34 to 3.47) | 0.002 |
| Stroke, yes/no | 1.98 (1.03 to 3.76) | 0.04 | 1.98 (1.04 to 3.78) | 0.04 |
| Diabetes, yes/no | 1.96 (1.18 to 3.26) | 0.01 | 1.96 (1.18 to 3.26) | 0.009 |
| LogeCRP,a per 1 unit | 1.40 (1.13 to 1.73) | 0.001 | 1.42 (1.15 to 1.75) | 0.001 |
| SBP, per 10 mm Hg | 1.19 (1.08 to 1.31) | 0.001 | 1.18 (1.08 to 1.31) | 0.001 |
| Albumin,a per 10 units | 0.62 (0.40 to 0.95) | 0.03 | 0.59 (0.38 to 0.89) | 0.01 |
| Hemoglobin,a per 10 units | 0.92 (0.77 to 1.10) | 0.35 | ||
| ESA,b per 100 units | 1.00 (1.00 to 1.00) | 0.98 | ||
| IV iron dose,b per 100 units | 0.97 (0.81 to 1.15) | 0.71 |
CRP, C-reactive protein; SBP, systolic BP; ESA, erythropoiesis-stimulating agent; IV, intravenous.
a
Hemoglobin, ESA, and IV iron dose used for this analysis are time-varying variables on the basis of the most recent previous level over the postrandomization values for each variable during the trial.
b
Hemoglobin, ESA, and IV iron dose used for this analysis are time-varying variables on the basis of the mean of previous levels over the postrandomization values for each variable during the trial.